Overview
Spherix’s coverage of the psoriatic arthritis market provides a full-picture analysis of the current PsA market landscape in the US and EU5, as well as perceptions and uptake of new entrants. Insights serve to bolster understanding of the market and provide input for brand commercialization plans.
Services Available
Trending market evolution
-
Psoriatic Arthritis (US) - quarterly, n=100
-
Psoriatic Arthritis (EU) - semiannual, n=250
Exploring the patient journey
-
Biologic/Small Molecule Switching in Psoriatic Arthritis (US) - annual, n=1,000 patient charts
Benchmarking new brand performance
-
Tremfya (Janssen) in Psoriatic Arthritis (US)
-
Rinvoq (AbbVie) in Psoriatic Arthritis (US)*
-
Skyrizi (AbbVie) in Psoriatic Arthritis*
*Pending approvals and launch